CS
IGMS

Candriam SCA’s IGM Biosciences IGMS Stock Holding History

Candriam SCA’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-175,008
Closed -$1.46M – 713
2023
Q3 		$1.46M Hold
175,008
– – 0.01% 494
2023
Q2 		$1.62M Sell
175,008
-12,791
-7% -$143K 0.01% 537
2023
Q1 		$2.38M Buy
187,799
+28,814
+18% +$596K 0.02% 536
2022
Q4 		$2.7M Buy
158,985
+110,225
+226% +$2.2M 0.02% 518
2022
Q3 		$1.11M Buy
+48,760
New +$985K 0.01% 687
2021
Q3 		– Sell
-122,029
Closed -$10.2M – 891
2021
Q2 		$10.2M Buy
122,029
+13,137
+12% +$973K 0.07% 282
2021
Q1 		$9.23M Hold
108,892
– – 0.08% 265
2020
Q4 		$9.61M Sell
108,892
-21,395
-16% -$1.5M 0.08% 271
2020
Q3 		$9.62M Sell
130,287
-6,081
-4% -$360K 0.09% 245
2020
Q2 		$9.96M Buy
136,368
+136,360
+1,704,500% +$8.28M 0.11% 217
2020
Q1 		$0 Buy
+8
New +$351 ﹤0.01% 794

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Candriam SCA's IGMS Position: Q4 2023 in Review

Candriam SCA sold out of IGM Biosciences (IGMS) in Q4 2023, closing a stake of 175,008 shares — an estimated $1.46M sold.

Candriam SCA first reported a position in IGMS in Q1 2020 and held it in 11 quarters. The position peaked at $10.2M in Q2 2021. 72 funds tracked by Wall St. Rank hold IGMS as of Q4 2023.

  • Candriam SCA reported no remaining IGM Biosciences position as of Q4 2023 after selling out during the quarter.
  • Candriam SCA sold 175,008 IGM Biosciences shares in Q4 2023, an estimated $1.46M.
  • Candriam SCA first reported a position in IGM Biosciences in Q1 2020 and held it in 11 quarters.
  • Candriam SCA's IGM Biosciences position peaked at $10.2M in Q2 2021.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2023.

Based on Candriam SCA's 13F filing for Q4 2023, filed 14 Feb 2024.